“You often learn from when science goes the opposite direction from what you expect,” said presenter David Berg, MD. The next question to answer is what role GDF-15 plays in heart failure. #HFSA2025 #CardioSky
Lowering Novel Biomarker, GDF-15, Raises HF Event Rate: GARDEN-TIMI 74
Lowering Novel Biomarker, GDF-15, Raises HF Event Rate: GARDEN-TIMI 74
Lowering Novel Biomarker, GDF-15, Raises HF Event Rate: GARDEN-TIMI 74
cmacahilig@crf.org
Tue, 09/30/2025 - 14:33
Yael L. Maxwell
Despite success in some cancer patients, a drug that neutralizes GDF-15 was clearly harmful in HF patients. The question is, why?
www.tctmd.com
October 1, 2025 at 1:13 PM
“You often learn from when science goes the opposite direction from what you expect,” said presenter David Berg, MD. The next question to answer is what role GDF-15 plays in heart failure. #HFSA2025 #CardioSky
6 DAYS LEFT 🚨 Share your research with the #heartfailure community!
#HFSA2025 is the perfect place to put a spotlight on important research being conducted by researchers at all career levels and disciplines.
Submit your science by March 17th! hfsa.org/asm/submitti... #CardioSky
#HFSA2025 is the perfect place to put a spotlight on important research being conducted by researchers at all career levels and disciplines.
Submit your science by March 17th! hfsa.org/asm/submitti... #CardioSky
March 11, 2025 at 7:59 PM
6 DAYS LEFT 🚨 Share your research with the #heartfailure community!
#HFSA2025 is the perfect place to put a spotlight on important research being conducted by researchers at all career levels and disciplines.
Submit your science by March 17th! hfsa.org/asm/submitti... #CardioSky
#HFSA2025 is the perfect place to put a spotlight on important research being conducted by researchers at all career levels and disciplines.
Submit your science by March 17th! hfsa.org/asm/submitti... #CardioSky
#HFSA2025 Early Bird Registration is now open! Here's how you can claim the lowest prices of the year:
✅ Become an HFSA member
✅ Register before June 30 to claim the early bird discount
✅ Save $100 when you register for both ASM 2025 and the HFSA Devices in HF Meeting
hfsa.org/asm/registra...
✅ Become an HFSA member
✅ Register before June 30 to claim the early bird discount
✅ Save $100 when you register for both ASM 2025 and the HFSA Devices in HF Meeting
hfsa.org/asm/registra...
June 10, 2025 at 3:55 PM
#HFSA2025 Early Bird Registration is now open! Here's how you can claim the lowest prices of the year:
✅ Become an HFSA member
✅ Register before June 30 to claim the early bird discount
✅ Save $100 when you register for both ASM 2025 and the HFSA Devices in HF Meeting
hfsa.org/asm/registra...
✅ Become an HFSA member
✅ Register before June 30 to claim the early bird discount
✅ Save $100 when you register for both ASM 2025 and the HFSA Devices in HF Meeting
hfsa.org/asm/registra...
Ronald Witteles, MD presented on outcomes of vutrisiran monotherapy (vs placebo) in HELIOS-B with and without censoring tafamidis drop ins
#HFSA2025
#MedIQHFSA2025
#HFSA2025
#MedIQHFSA2025
September 29, 2025 at 4:27 PM
Ronald Witteles, MD presented on outcomes of vutrisiran monotherapy (vs placebo) in HELIOS-B with and without censoring tafamidis drop ins
#HFSA2025
#MedIQHFSA2025
#HFSA2025
#MedIQHFSA2025
#HFSA2025 is just around the corner. Let’s exchange ideas on advancing heart failure care and see firsthand how Murj transforms fragmented cardiac device data from a burden into a strategic asset.
📅 September 26–29
📍 Booth 332 | Minneapolis
🤝 Book time to exchange ideas with our team bit.ly/45XhV18
📅 September 26–29
📍 Booth 332 | Minneapolis
🤝 Book time to exchange ideas with our team bit.ly/45XhV18
September 18, 2025 at 5:38 PM
#HFSA2025 is just around the corner. Let’s exchange ideas on advancing heart failure care and see firsthand how Murj transforms fragmented cardiac device data from a burden into a strategic asset.
📅 September 26–29
📍 Booth 332 | Minneapolis
🤝 Book time to exchange ideas with our team bit.ly/45XhV18
📅 September 26–29
📍 Booth 332 | Minneapolis
🤝 Book time to exchange ideas with our team bit.ly/45XhV18
Selective in vitro enhancement of cardiac myosin motor function and myofilament force generation by danicamtiv prompted clinical evaluation. A short course of danicamtiv was generally well tolerated in participants with #DCM https://bit.ly/4mE3vcM
#HFSA2025 #JACC #cvGenetics @jimjanuzzi.bsky.social
#HFSA2025 #JACC #cvGenetics @jimjanuzzi.bsky.social
September 29, 2025 at 3:33 PM
Selective in vitro enhancement of cardiac myosin motor function and myofilament force generation by danicamtiv prompted clinical evaluation. A short course of danicamtiv was generally well tolerated in participants with #DCM https://bit.ly/4mE3vcM
#HFSA2025 #JACC #cvGenetics @jimjanuzzi.bsky.social
#HFSA2025 #JACC #cvGenetics @jimjanuzzi.bsky.social
Efficacy of vutrisiran in HELIOS-B by baseline health status (KCCQ) - consistent effects across the different categories analyzed
#HFSA2025
#MedIQHFSA2025
#HFSA2025
#MedIQHFSA2025
September 29, 2025 at 4:27 PM
Efficacy of vutrisiran in HELIOS-B by baseline health status (KCCQ) - consistent effects across the different categories analyzed
#HFSA2025
#MedIQHFSA2025
#HFSA2025
#MedIQHFSA2025
Come see us at #THT2025 - Booth #16! Learn more about submitting your science for publication in JCF-Intersections, get signed up for the latest HFSA Devices in Heart Failure Meeting news, and pick up some #HFSA2025 swag! @jcardfail.bsky.social
February 11, 2025 at 5:40 PM
Come see us at #THT2025 - Booth #16! Learn more about submitting your science for publication in JCF-Intersections, get signed up for the latest HFSA Devices in Heart Failure Meeting news, and pick up some #HFSA2025 swag! @jcardfail.bsky.social
At #HFSA2025, we spoke with Justin Ezekowitz, MD, co-director of the Canadian VIGOUR Center, to discuss his analysis of background therapies in the VICTOR trial of vericiguat in HFrEF.
Watch now:
Watch now:
Vericiguat Improves HFrEF Regardless of Background Therapy, With Justin Ezekowitz, MD | HCPLive
Ezekowitz spotlights improvement in cardiovascular mortality and heart failure hospitalization despite a failure to achieve the primary endpoint of VICTOR.
www.hcplive.com
October 18, 2025 at 2:00 PM
At #HFSA2025, we spoke with Justin Ezekowitz, MD, co-director of the Canadian VIGOUR Center, to discuss his analysis of background therapies in the VICTOR trial of vericiguat in HFrEF.
Watch now:
Watch now:
🚨 #HFSA2025 SimPub alert!
The Heart Failure Society America’s 2025 Annual Scientific Meeting kicks off today, and JCF has 12 simultaneous publications releasing during the meeting!
The Heart Failure Society America’s 2025 Annual Scientific Meeting kicks off today, and JCF has 12 simultaneous publications releasing during the meeting!
September 26, 2025 at 11:15 PM
🚨 #HFSA2025 SimPub alert!
The Heart Failure Society America’s 2025 Annual Scientific Meeting kicks off today, and JCF has 12 simultaneous publications releasing during the meeting!
The Heart Failure Society America’s 2025 Annual Scientific Meeting kicks off today, and JCF has 12 simultaneous publications releasing during the meeting!
Continues acoramidis reduced ACM/CVH from the parent study to the OLE portion at Month 42
#HFSA2025
#MedIQHFSA2025
#HFSA2025
#MedIQHFSA2025
September 29, 2025 at 4:27 PM
Continues acoramidis reduced ACM/CVH from the parent study to the OLE portion at Month 42
#HFSA2025
#MedIQHFSA2025
#HFSA2025
#MedIQHFSA2025
Disappointingly, a growth differentiation factor 15 neutralizer not only failed to improve functional outcomes in heart failure but was associated with harm in a trial that was terminated early. #HFSA2025
https://www.medpagetoday.com/meetingcoverage/hfsa/117753
https://www.medpagetoday.com/meetingcoverage/hfsa/117753
Ponsegromab Crashes Out in Frailer Heart Failure Patients
GDF-15 suppression of no help, in fact increased HF risk, systemic inflammation
www.medpagetoday.com
October 4, 2025 at 3:25 PM
Disappointingly, a growth differentiation factor 15 neutralizer not only failed to improve functional outcomes in heart failure but was associated with harm in a trial that was terminated early. #HFSA2025
https://www.medpagetoday.com/meetingcoverage/hfsa/117753
https://www.medpagetoday.com/meetingcoverage/hfsa/117753
Thank you to Ahmad Masri, MD, for his live updates on emerging and potentially practice-changing clinical data on advances in the treatment of #ATTR-CM from #HFSA2025.
Check out this thread for highlights.
#MedIQHFSA2025
Check out this thread for highlights.
#MedIQHFSA2025
September 29, 2025 at 4:27 PM
Thank you to Ahmad Masri, MD, for his live updates on emerging and potentially practice-changing clinical data on advances in the treatment of #ATTR-CM from #HFSA2025.
Check out this thread for highlights.
#MedIQHFSA2025
Check out this thread for highlights.
#MedIQHFSA2025
“The time-sensitive nature of transthyretin cardiomyopathy is something that has been on many people’s minds, but I think this is the first piece of evidence that should push us forward,” said Ahmad Masri, MD at #HFSA2025. #CardioSky
Acoramidis Halves Cumulative CV Events Within 6 Months: ATTRibute-CM
Acoramidis Halves Cumulative CV Events Within 6 Months: ATTRibute-CM
Acoramidis Halves Cumulative CV Events Within 6 Months: ATTRibute-CM
cmacahilig@crf.org
Wed, 10/01/2025 - 14:58
Yael L. Maxwell
The exploratory, post hoc look at the trial shows curves starting to separate by month 1, supporting earlier treatment.
www.tctmd.com
October 1, 2025 at 7:22 PM
“The time-sensitive nature of transthyretin cardiomyopathy is something that has been on many people’s minds, but I think this is the first piece of evidence that should push us forward,” said Ahmad Masri, MD at #HFSA2025. #CardioSky
The first plenary session at #HFSA2025 is about to begin and all of my coverage will be on @tctmd.bsky.social! Who else is here and what are you looking forward to at the meeting?
September 27, 2025 at 1:54 PM
The first plenary session at #HFSA2025 is about to begin and all of my coverage will be on @tctmd.bsky.social! Who else is here and what are you looking forward to at the meeting?
As the @hfsa.bsky.social Annual Scientific Meeting 2025 comes to a close, here are the final #HFSA2025 SimPubs, out now in the Journal of Cardiac Failure. 🚨
🧵👇
🧵👇
September 28, 2025 at 10:39 PM
As the @hfsa.bsky.social Annual Scientific Meeting 2025 comes to a close, here are the final #HFSA2025 SimPubs, out now in the Journal of Cardiac Failure. 🚨
🧵👇
🧵👇
Data from ATTRibute-CM on acoramidis potentially preventing the progression of conduction disease as part of ATTR-CM presented at #HFSA2025
#MedIQHFSA2025
#MedIQHFSA2025
September 29, 2025 at 4:27 PM
Data from ATTRibute-CM on acoramidis potentially preventing the progression of conduction disease as part of ATTR-CM presented at #HFSA2025
#MedIQHFSA2025
#MedIQHFSA2025
CLOSING SOON❗
The ASM 2025 session proposal submission window closes tonight! Scientific Sessions make up the core of the meeting's program, delivering the most innovative, ground-breaking science from across the heart failure field.
Submit yours: hfsa.org/asm/session-...
#HFSA2025 #CardioSky
The ASM 2025 session proposal submission window closes tonight! Scientific Sessions make up the core of the meeting's program, delivering the most innovative, ground-breaking science from across the heart failure field.
Submit yours: hfsa.org/asm/session-...
#HFSA2025 #CardioSky
February 3, 2025 at 7:41 PM
CLOSING SOON❗
The ASM 2025 session proposal submission window closes tonight! Scientific Sessions make up the core of the meeting's program, delivering the most innovative, ground-breaking science from across the heart failure field.
Submit yours: hfsa.org/asm/session-...
#HFSA2025 #CardioSky
The ASM 2025 session proposal submission window closes tonight! Scientific Sessions make up the core of the meeting's program, delivering the most innovative, ground-breaking science from across the heart failure field.
Submit yours: hfsa.org/asm/session-...
#HFSA2025 #CardioSky
We presented exploratory data from ATTRibute-CM looking at all events - CVM and recurrent CVH - which show early and sustained effect of acoramidis throughout the study.
#HFSA2025
#MedIQHFSA2025
#HFSA2025
#MedIQHFSA2025
September 29, 2025 at 4:27 PM
We presented exploratory data from ATTRibute-CM looking at all events - CVM and recurrent CVH - which show early and sustained effect of acoramidis throughout the study.
#HFSA2025
#MedIQHFSA2025
#HFSA2025
#MedIQHFSA2025
Emily Martin presented on correlation of Tc-99m p5+14 in cardiac amyloidosis with clinical markers
#HFSA2025
#MedIQHFSA2025
#HFSA2025
#MedIQHFSA2025
September 29, 2025 at 4:27 PM
Emily Martin presented on correlation of Tc-99m p5+14 in cardiac amyloidosis with clinical markers
#HFSA2025
#MedIQHFSA2025
#HFSA2025
#MedIQHFSA2025
We’re excited to announce 2024’s Jay N. Cohn New Investigator Award winner Alvaro Delgado and runner-up Ameesh Isath, MD! If you are a young trainee/investigator, submit your research for #HFSA2025 for a chance to win an investigator award >> hfsa.org/asm/submitti... #CardioSky #HeartFailure
February 20, 2025 at 8:11 PM
We’re excited to announce 2024’s Jay N. Cohn New Investigator Award winner Alvaro Delgado and runner-up Ameesh Isath, MD! If you are a young trainee/investigator, submit your research for #HFSA2025 for a chance to win an investigator award >> hfsa.org/asm/submitti... #CardioSky #HeartFailure
We’re heading to #HFSA2025. Murj is shaping the future of cardiac device care—helping clinics move beyond fragmented data and legacy workflows to a modern, cloud-based platform.
September 2, 2025 at 7:21 PM
We’re heading to #HFSA2025. Murj is shaping the future of cardiac device care—helping clinics move beyond fragmented data and legacy workflows to a modern, cloud-based platform.
You're in luck 🍀 Less than 24 hours to submit your science for #HFSA2025!
Don't miss your chance to present your abstract to colleagues at the HFSA Annual Scientific Meeting! Your important research deserves to be seen.
Submit your general abstract: hfsa.org/asm/submitti...
Don't miss your chance to present your abstract to colleagues at the HFSA Annual Scientific Meeting! Your important research deserves to be seen.
Submit your general abstract: hfsa.org/asm/submitti...
March 17, 2025 at 6:15 PM
You're in luck 🍀 Less than 24 hours to submit your science for #HFSA2025!
Don't miss your chance to present your abstract to colleagues at the HFSA Annual Scientific Meeting! Your important research deserves to be seen.
Submit your general abstract: hfsa.org/asm/submitti...
Don't miss your chance to present your abstract to colleagues at the HFSA Annual Scientific Meeting! Your important research deserves to be seen.
Submit your general abstract: hfsa.org/asm/submitti...
Large dataset on V122I both homozygous and heterozygous from the VA presented at #HFSA2025
#MedIQHFSA2025
#MedIQHFSA2025
September 29, 2025 at 4:27 PM
Large dataset on V122I both homozygous and heterozygous from the VA presented at #HFSA2025
#MedIQHFSA2025
#MedIQHFSA2025
During #HFSA2025, we sat down with Barry Borlaug, MD, to discuss his prespecified analysis of sex differences with tirzepatide for obesity-related heart failure, based on results from the phase 3 SUMMIT trial.
Watch now:
Watch now:
Tirzepatide Affects Men and Women with HFpEF Equally, With Barry Borlaug, MD | HCPLive
A prespecified secondary analysis revealed no difference in male and female patients’ responses to tirzepatide in obesity-related HFpEF.
www.hcplive.com
October 11, 2025 at 2:00 PM
During #HFSA2025, we sat down with Barry Borlaug, MD, to discuss his prespecified analysis of sex differences with tirzepatide for obesity-related heart failure, based on results from the phase 3 SUMMIT trial.
Watch now:
Watch now: